As global equity markets expand, two corporate heavyweights are emerging as serious contenders to reach $1 trillion in market ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

Shares of pharmaceutical companies dropped early Monday after President Donald Trump said he would lower the cost of medicines for Americans by between 30% and 80%. Shares of major U.S. drugmakers Eli ...

Indian pharma stocks fell 1.6% on Monday, bucking broader market gains, after U.S. President Trump said he would cut drug ...

Investing.com -- U.S. stock futures rose sharply on Sunday evening after the White House announced a trade deal with China ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Bad reactions to popular weight-loss drugs, including Ozempic and Wegovy, are on track to soar by more than 350 per cent ...

USPS said its controllable loss was $848 million, up from $317 million in the same quarter last year as mail volume continues ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities ...